Pharmaceuticals, Biotechnology and Life Sciences
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON…
Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss TransactionTORONTO, March 07, 2022 (GLOBE NEWSWIRE)…
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation…
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in…
Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASH Receipt of a €4 m milestone payment from…
Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be…
FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of…
SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines…
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies,…